BPC-157: clinical evidence record
Also known as: Body Protection Compound 157, PL 14736, Pentadecapeptide BPC-157
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · BPC-157
Roughly 200 preclinical rodent papers since 2003, the majority from the Sikiric group at the University of Zagreb. No phase II or phase III randomised human clinical trials have been published. Independent replication outside the originating group remains limited.
Mechanism of action
How BPC-157 works
Synthetic 15-amino-acid peptide derived from a fragment of a protein found in human gastric juice. Proposed to modulate nitric oxide signalling, angiogenesis via VEGF upregulation, and growth-hormone receptor signalling at the site of injury in preclinical animal models.
Top peer-reviewed citations
Selection of the most-cited peer-reviewed literature on BPC-157. Where a verified PMID or DOI is shown, the citation links to the original record. Other citations list the title, authors, journal and year so the reader can locate the paper through the journal index or the PubMed search linked below. PeptideClear publishes editorial commentary, not clinical guidance.
-
Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Sikiric P, Rucman R, Turkovic B, et al.. Current Neuropharmacology, 2016.
-
BPC 157 and Standard Angiogenic Growth Factors
Sikiric P, Seiwerth S, Rucman R, et al.. Current Pharmaceutical Design, 2018.
-
Stable gastric pentadecapeptide BPC 157 and wound healing
Sikiric P, Skrtic A, Gojkovic S, et al.. Frontiers in Pharmacology, 2021.
-
Achilles tendon transection: BPC 157 healing effect in rats
Krivic A, Anic T, Seiwerth S, et al.. Journal of Orthopaedic Research, 2006.
-
Pentadecapeptide BPC 157 reduces bleeding and thrombosis
Stupnisek M, Kokot A, Drmic D, et al.. PLOS One, 2015.
-
BPC 157 counteracts QTc prolongation induced by neuroleptics
Strinic D, Belosic Halle Z, Luetic K, et al.. Life Sciences, 2017.
-
Effect of pentadecapeptide BPC 157 on gastrointestinal lesions
Sikiric P, Petek M, Rucman R, et al.. Journal of Physiology Paris, 1993.
-
BPC 157 and the central nervous system
Sikiric P, Hahm KB, Blagaic AB, et al.. Neural Regeneration Research, 2022.
-
Stable gastric pentadecapeptide BPC 157 in tendon regeneration
Chang CH, Tsai WC, Lin MS, et al.. Journal of Applied Physiology, 2011.
-
BPC 157 as a potential treatment for inflammatory bowel disease
Sikiric P, Seiwerth S, Brcic L, et al.. Inflammopharmacology, 2010.
Full PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157+Sikiric.
UK regulatory status
Plain-English summary of where BPC-157 sits under the four UK and international frameworks that govern peptide supply. Editorial commentary, not legal advice.
- Misuse of Drugs Act 1971: Not controlled under the Misuse of Drugs Act 1971.
- Psychoactive Substances Act 2016: Not scheduled under the Psychoactive Substances Act 2016.
- MHRA medicines classification: No UK marketing authorisation as a medicine.
- WADA Prohibited List: WADA Prohibited List S0 (non-approved substances), prohibited at all times.
Full regulatory record: BPC-157 UK regulatory status.
Risks and unknowns
What the literature does not yet show about BPC-157
Known concerns
- Most published efficacy claims for BPC-157 require careful interpretation. Read the cited papers in full before drawing conclusions.
- Purity of UK research-peptide supply varies between retailers. Certificates of analysis and HPLC documentation differ.
- Cold-chain handling between manufacture and delivery is not standardised across the research-peptide market.
- Independent replication of single-group findings is the key check on any preclinical claim.
Open questions in the literature
- Where human pharmacokinetics have not been formally characterised, dose translation from animal models is not reliable.
- Long-term safety profile beyond the duration of published studies remains an open question.
- Interactions with other prescribed or unlicensed substances are typically not studied.
Regulatory note
No UK marketing authorisation as a medicine. Prohibited at all times under WADA S0 (non-approved substances). The moment a UK seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Related reading on PeptideClear
Frequently asked questions
What is the evidence level for BPC-157?
What is the UK regulatory status of BPC-157?
Has BPC-157 been tested in human clinical trials?
Where can I read the source literature for BPC-157?
Last verified 2026-05-22. Editorial commentary, not legal or clinical advice. Citations without a linked identifier can be located through the PubMed search and the journal index.